Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy, Immunogenicity, and Safety Study of Clostridium difficile Toxoid Vaccine in At-Risk Adults
2013-000775-32Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Clostridioides difficile colitis (CDI) comparing Clostridium difficile toxoid vaccine with Placebo (2 arms). Primary endpoint: Symptomatic PCR-confirmed primary C. difficile infection. Started Jun 2013; status: completed.
02
Drugs
ACAM-CDIFF
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2013-000775-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000775-32.